Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
Abstract Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 201...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-11-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-017-1341-2 |
id |
doaj-aff33776974e42f8b672304e627ad57e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Paolo A. Ascierto Sanjiv S. Agarwala Gennaro Ciliberto Sandra Demaria Reinhard Dummer Connie P. M. Duong Soldano Ferrone Silvia C. Formenti Claus Garbe Ruth Halaban Samir Khleif Jason J. Luke Lluis M. Mir Willem W. Overwijk Michael Postow Igor Puzanov Paul Sondel Janis M. Taube Per Thor Straten David F. Stroncek Jennifer A. Wargo Hassane Zarour Magdalena Thurin |
spellingShingle |
Paolo A. Ascierto Sanjiv S. Agarwala Gennaro Ciliberto Sandra Demaria Reinhard Dummer Connie P. M. Duong Soldano Ferrone Silvia C. Formenti Claus Garbe Ruth Halaban Samir Khleif Jason J. Luke Lluis M. Mir Willem W. Overwijk Michael Postow Igor Puzanov Paul Sondel Janis M. Taube Per Thor Straten David F. Stroncek Jennifer A. Wargo Hassane Zarour Magdalena Thurin Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 Journal of Translational Medicine Melanoma Immunotherapy Cancer Checkpoint blockade updates Combination therapies Biomarkers |
author_facet |
Paolo A. Ascierto Sanjiv S. Agarwala Gennaro Ciliberto Sandra Demaria Reinhard Dummer Connie P. M. Duong Soldano Ferrone Silvia C. Formenti Claus Garbe Ruth Halaban Samir Khleif Jason J. Luke Lluis M. Mir Willem W. Overwijk Michael Postow Igor Puzanov Paul Sondel Janis M. Taube Per Thor Straten David F. Stroncek Jennifer A. Wargo Hassane Zarour Magdalena Thurin |
author_sort |
Paolo A. Ascierto |
title |
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 |
title_short |
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 |
title_full |
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 |
title_fullStr |
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 |
title_full_unstemmed |
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 |
title_sort |
future perspectives in melanoma research “melanoma bridge”, napoli, november 30th–3rd december 2016 |
publisher |
BMC |
series |
Journal of Translational Medicine |
issn |
1479-5876 |
publishDate |
2017-11-01 |
description |
Abstract Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 2011, the rise to nearly 50% in the setting of treatment with Ipilimumab, and rise to 70% with BRAF inhibitor monotherapy in 2013 was observed. Even more impressive are 1-year survival rates considering combination strategies with both targeted therapy and immunotherapy, now exceeding 80%. Can we improve response rates even further, and bring these therapies to more patients? In fact, despite these advances, responses are heterogeneous and are not always durable. There is a critical need to better understand who will benefit from therapy, as well as proper timing, sequence and combination of different therapeutic agents. How can we better understand responses to therapy and optimize treatment regimens? The key to better understanding therapy and to optimizing responses is with insights gained from responses to targeted therapy and immunotherapy through translational research in human samples. Combination therapies including chemotherapy, radiotherapy, targeted therapy, electrochemotherapy with immunotherapy agents such as Immune Checkpoint Blockers are under investigation but there is much room for improvement. Adoptive T cell therapy including tumor infiltrating lymphocytes and chimeric antigen receptor modified T cells therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Tumor infiltrating lymphocytes therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Understanding the mechanisms behind the development of acquired resistance and tests for biomarkers for treatment decisions are also under study and will offer new opportunities for more efficient combination therapies. Knowledge of immunologic features of the tumor microenvironment associated with response and resistance will improve the identification of patients who will derive the most benefit from monotherapy and might reveal additional immunologic determinants that could be targeted in combination with checkpoint blockade. The future of advanced melanoma needs to involve education and trials, biobanks with a focus on primary tumors, bioinformatics and empowerment of patients and clinicians. |
topic |
Melanoma Immunotherapy Cancer Checkpoint blockade updates Combination therapies Biomarkers |
url |
http://link.springer.com/article/10.1186/s12967-017-1341-2 |
work_keys_str_mv |
AT paoloaascierto futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT sanjivsagarwala futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT gennarociliberto futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT sandrademaria futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT reinharddummer futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT conniepmduong futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT soldanoferrone futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT silviacformenti futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT clausgarbe futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT ruthhalaban futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT samirkhleif futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT jasonjluke futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT lluismmir futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT willemwoverwijk futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT michaelpostow futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT igorpuzanov futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT paulsondel futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT janismtaube futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT perthorstraten futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT davidfstroncek futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT jenniferawargo futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT hassanezarour futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 AT magdalenathurin futureperspectivesinmelanomaresearchmelanomabridgenapolinovember30th3rddecember2016 |
_version_ |
1725902574175911936 |
spelling |
doaj-aff33776974e42f8b672304e627ad57e2020-11-24T21:46:01ZengBMCJournal of Translational Medicine1479-58762017-11-0115113110.1186/s12967-017-1341-2Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016Paolo A. Ascierto0Sanjiv S. Agarwala1Gennaro Ciliberto2Sandra Demaria3Reinhard Dummer4Connie P. M. Duong5Soldano Ferrone6Silvia C. Formenti7Claus Garbe8Ruth Halaban9Samir Khleif10Jason J. Luke11Lluis M. Mir12Willem W. Overwijk13Michael Postow14Igor Puzanov15Paul Sondel16Janis M. Taube17Per Thor Straten18David F. Stroncek19Jennifer A. Wargo20Hassane Zarour21Magdalena Thurin22Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”Oncology & Hematology, St. Luke’s University Hospital and Temple UniversityIRCCS “Regina Elena” National Cancer InstituteRadiation Oncology and Pathology, Weill Cornell Medical CollegeDepartment of Dermatology, University of Zurich HospitalINSERM (National Institute of Health and Medical Research), Institut Gustave RoussyMassachusetts General HospitalDepartment of Radiation Oncology, Weill Cornell Medical CollegeDivision of Dermatologic Oncology, Department of Dermatology, Eberhard Karls UniversityDepartment of Dermatology, Yale University School of MedicineGeorgia Cancer Center, Augusta UniversityDepartment of Hematology/Oncology, University of Chicago Comprehensive Cancer CenterCNRS (National Center for Scientific Research, France), University Paris-Saclay, Gustave RoussyDivision of Cancer Medicine, Department of Melanoma Medical Oncology-Research, University of Texas MD Anderson Cancer CenterDepartment of Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Medicine, Roswell Park Cancer InstitutePediatrics, Human Oncology and Genetics, University of WisconsinJohns Hopkins University School of MedicineCenter for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital HerlevClinical Center, National Institutes of HealthDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer CenterMedicine, Immunology and Dermatology Institute, University of Pittsburgh School of MedicineCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIHAbstract Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 2011, the rise to nearly 50% in the setting of treatment with Ipilimumab, and rise to 70% with BRAF inhibitor monotherapy in 2013 was observed. Even more impressive are 1-year survival rates considering combination strategies with both targeted therapy and immunotherapy, now exceeding 80%. Can we improve response rates even further, and bring these therapies to more patients? In fact, despite these advances, responses are heterogeneous and are not always durable. There is a critical need to better understand who will benefit from therapy, as well as proper timing, sequence and combination of different therapeutic agents. How can we better understand responses to therapy and optimize treatment regimens? The key to better understanding therapy and to optimizing responses is with insights gained from responses to targeted therapy and immunotherapy through translational research in human samples. Combination therapies including chemotherapy, radiotherapy, targeted therapy, electrochemotherapy with immunotherapy agents such as Immune Checkpoint Blockers are under investigation but there is much room for improvement. Adoptive T cell therapy including tumor infiltrating lymphocytes and chimeric antigen receptor modified T cells therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Tumor infiltrating lymphocytes therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Understanding the mechanisms behind the development of acquired resistance and tests for biomarkers for treatment decisions are also under study and will offer new opportunities for more efficient combination therapies. Knowledge of immunologic features of the tumor microenvironment associated with response and resistance will improve the identification of patients who will derive the most benefit from monotherapy and might reveal additional immunologic determinants that could be targeted in combination with checkpoint blockade. The future of advanced melanoma needs to involve education and trials, biobanks with a focus on primary tumors, bioinformatics and empowerment of patients and clinicians.http://link.springer.com/article/10.1186/s12967-017-1341-2MelanomaImmunotherapyCancerCheckpoint blockade updatesCombination therapiesBiomarkers |